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We appreciate the correspondence from Drs. Gratwohl,
van Biezen, Hemans, and Apperly for the Chro n i c
Leukemia Working Party for the European Group for
Blood and Marrow Transplantation re g a rding our study on
the role of splenic irradiation in patients with chronic myel-
ogenous leukemia undergoing an allogeneic bone marro w
transplant [1]. The results they present are similar to those
re p o rted in our study. The mean Sokal’s score in our
patient group was >0.8, and 41% of the patients were in the
i n t e rmediate-high risk group. We found no diff e rence in
overall or disease-free survival with the addition of splenic
radiation for the low and intermediate risk groups, 89%
and 80%, re s p e c t i v e l y. None of our patients received a
T cell–depleted marrow and all received cyclosporin and
s h o rt-course methotrexate for graft-versus-host-disease
p ro p h y l a x i s .
We believe that the effects of splenic irradiation may be
more than just a reduction of tumor load. Splenic irradiation
may contribute to or modify the development of both acute
and chronic graft-versus-host disease [2]. In addition, the
5 100-cGy fractions administered in our study did not
appear to ablate splenic function and increase the risk of
t r a n s p l a n t - related morbidity or mort a l i t y. In prior studies,
higher doses of irradiation therapy were administered to the
spleen, which has been shown to significantly impair splenic
function and increase the transplant-related mortality as
reported by Gratwohl and others [3,4].
We agree with Dr. Gratwohl and colleagues that splenic
irradiation should be considered as part of the BMT treat-
ment schedule for patients with chronic myeloid leukemia
undergoing a non–T-cell depleted bone marrow transplant.
The lower doses of radiation used in our study may decrease
the transplant-related mortality but pre s e rve the benefic i a l
e ffect. More o v e r, with the expanding use of less intensive
preparative regimens to induce mixed chimerism, the role of
splenic irradiation may have an important immunomodula-
tory effect and should be further evaluated.
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